One thought on “What is the status of the antivirals lopinavir/ritonavir in the treatment of coronavirus disease 2019 (COVID-19)?”
Arti says:
Critical COVID-19 may be associated with respiratory failure, shock, or multiorgan system dysfunction. It selectively inhibits RNA polymerase, which is necessary for viral replication. The UK RECOVERY trial showed that low-dose dexamethasone (6 mg PO or IV daily for 10 days) randomized to 2104 patients reduced deaths by 35% in ventilated patients (P = 0. The UK RECOVERY trial showed that low-dose dexamethasone (6 mg PO or IV daily for 10 days) randomized to 2104 patients reduced de
Critical COVID-19 may be associated with respiratory failure, shock, or multiorgan system dysfunction. It selectively inhibits RNA polymerase, which is necessary for viral replication. The UK RECOVERY trial showed that low-dose dexamethasone (6 mg PO or IV daily for 10 days) randomized to 2104 patients reduced deaths by 35% in ventilated patients (P = 0. The UK RECOVERY trial showed that low-dose dexamethasone (6 mg PO or IV daily for 10 days) randomized to 2104 patients reduced de